885069-29-4

Usage

Physical state

Colorless to pale yellow liquid

Odor

Slightly sweet

Uses

Intermediate in the synthesis of pharmaceuticals and agrochemical products; building block in the production of other organic compounds

Toxicity

Low, not expected to cause harm to human health or the environment with proper safety precautions.

Upstream product

• 21739-92-4 5-bromo-2-chlorobenzoic acid 
• 676-58-4 methylmagnesium chloride 
• 76008-73-6 5-Bromo-2-chloro-benzoic acid ethyl ester 
• 251085-87-7 methyl 5-bromo-2-chloro-benzoate 
• 74-88-4 methyl iodide 
• 917-64-6 methyl magnesium iodide 
• 75-16-1 methylmagnesium bromide 

Downstream Products

• 945717-56-6 4-bromo-1-chloro-2-(prop-1-en-2-yl)benzene 
• 1318793-71-3 1-{4-chloro-3-[(dimethyl)(4-ethyloxyphenyl)methyl]phenyl}-1-deoxy-β-D-glucopyranose 
• 1318794-43-2 2,3,4,6-tetra-O-acetyl-1-deoxy-1-{4-chloro-3-[1-(4-ethoxyphenyl)-1-methylethyl]phenyl}-β-D-glucopyranose 
• 1318794-42-1 1-{4-chloro-3-[(dimethyl)(4-ethyloxyphenyl)methyl]phenyl}-1-deoxy-α/β-D-glucopyranose 
• 1318794-39-6 (5-bromo-2-chlorophenyl)(4-ethyloxyphenyl)(dimethyl)methane 
• 1318794-41-0 1-{4-chloro-3-[(dimethyl)(4-ethyloxyphenyl)methyl]phenyl}-α/β-D-methyl glucopyranoside 
• 461432-25-7 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 885069-30-7 2-[2-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propan-2-ol 
• 1443151-77-6 2-{2-chloro-5-[4-( {2-[4-(fluoromethoxy)phenyl]ethyl}amino)-6-methoxy-1,3,5-triazin-2-yl]phenyl}propan-2-ol 
• 1443151-54-9 2-{2-chloro-5-[4-({2-[4-(difluoromethoxy)phenyl]ethyl}amino)-6-methoxy-1,3,5-triazin-2-yl]phenyl}propan-2-ol 
• 1443151-98-1 4-[2-({4-[4-Chloro-3-(1-hydroxy-1-methylethyl)phenyl]-6-methoxy-1,3,5-triazin-2-yl}amino)ethyl]phenol 

Relevant academic research and scientific papers

STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI

The present invention relates to novel strobilurine type compounds, to compositions comprising at least one such compound, to methods for combating phytopathogenic fungi, to the use of such compounds and to seeds coated with at least one such compound.

1,3,5-TRIAZINE-2-AMINE DERIVATIVES, PREPARATION THEREOF AND DIAGNOSTIC AND THERAPEUTIC USE THEREOF

The present invention relates to compounds corresponding to formula (I) in which: - R1 represents a substituted phenyl; - R2 represents: - a substituted phenyl; - a heteroaromatic group, the said group being unsubstituted or substituted one or more times; - R3 represents a group Alk; - R4 represents a hydrogen atom or a (C1-C4)alkyl; - R5 represents a hydrogen atom, a (C3-C6)cycloalkyl or a (C1-C4)alkyl-O-Alk; - or alternatively R4 and R5, together with the nitrogen atom to which they are attached, constitute a heterocyclic radical chosen from: azetidin-1-yl, pyrrolidin-1-yl, piperid-1-yl, morpholin-4-yl; - R6 represents a group -COOAlk, a group -CONH2 or a group -NHSO2 Alk; - Alk represents a (C1-C4)alkyl, which is unsubstituted or substituted one or more times with a halogen atom; in the form of the base or of an acid-addition salt. Preparation process and diagnostic and therapeutic use

PHENYL C-GLUCOSIDE DERIVATIVES, PREPARATION METHODS AND USES THEREOF

The present invention relates to a sodium glucose cotransporter 2 (SGLT2) inhibitor with a phenyl C-glucoside structure, its preparation method, a pharmaceutical composition containing the same, and its use in treating diabetes and preparing an anti-diabetes medicament. The invention provides a compound with the structure of general formula I and a pharmaceutically acceptable salt and prodrug ester thereof, wherein, the definitions of R5 and R6 are selected from the following: (1) R5=R6=Me; (2) R5=Me, R6=OMe; (3) R5=Me, R6=H; (4) R5=Me, R6=F; (5) R5=F, R6=H; and (6) R5=OMe, R6=H.

PHENYL C-GLUCOSIDE DERIVATIVES, PREPARATION METHODS AND USES THEREOF

The present invention relates to a sodium glucose cotransporter 2 (SGLT2) inhibitor with a phenyl C-glucoside structure, its preparation method, a pharmaceutical composition containing the same, and its use in treating diabetes and preparing an anti-diabetes medicament. The invention provides a compound with the structure of general formula I and a pharmaceutically acceptable salt and prodrug ester thereof, wherein, the definitions of R5 and R6 are selected from the following: (1) R5 = R6 = Me; (2) R5 =Me, R6 = OMe; (3) R5 =Me, R6 = H; (4) R5 =Me, R6 = F; (5) R5 = F, R6 = H; and (6) R5 = OMe, R6 = H.

Gem-dimethyl-bearing C-glucosides as sodium-glucose co-transporter 2 (SGLT2) inhibitors

Three novel gem-dimethyl C-glucosides were designed as sodium-glucose co-transporter 2 (SGLT2) inhibitors, and their syntheses started from D-glucose and three 2-substituted-5-bromobenzoic acids were achieved via a facile 8-step protocol, with the key step being anhydrous aluminum chloride-catalyzed Friedel-Crafts alkylation of tertiary alcohols and phenetol. These three SGLT2 inhibitors were evaluated in vivo with a mice oral glucose tolerance test (OGTT), and the anti-hyperglycemic activities of all these three compounds were comparable with that of the positive control Dapagliflozin. Copyright

Heteroaryl and benzyl amide compounds

Compounds of formula I wherein R1, R2, R4, R5, A, B, D and n are as defined, and pharmaceutically acceptable salts thereof, processes for their preparation, their use as pharmaceuticals and pharmaceutical compositions comprising them.